Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - docetaxel -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - docetaxel -

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin lispro - diabetes mellitus - drugs used in diabetes - for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. insulin lispro sanofi is also indicated for the initial stabilisation of diabetes mellitus.

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin aspart - diabetes mellitus - drugs used in diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Israel - English - Ministry of Health

sanofi israel ltd - dupilumab - solution for injection - dupilumab 150 mg/ml - dupilumab - atopic dermatitisdupixent is indicated for the treatment of treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (ad) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. dupixent can be used with or without topical corticosteroids.asthmadupixent is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.limitation of usedupixent is not indicated for the relief of acute bronchospasm or status asthmaticus. chronic rhinosinusitis with nasal polyposisdupixent 300mg is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (crswnp).eosinophilic esophagitisdupixent is indicated for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (eoe).prurigo nodularisdupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy.

Israel - English - Ministry of Health

sanofi israel ltd - dupilumab - solution for injection - dupilumab 175 mg/ml - dupilumab - atopic dermatitis dupixent is indicated for the treatment of treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (ad) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. dupixent can be used with or without topical corticosteroids. asthma dupixent is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. limitation of use: dupixent is not indicated for the relief of acute bronchospasm or status asthmaticus.

Israel - English - Ministry of Health

sanofi israel ltd - insulin glargine; lixisenatide - solution for injection - lixisenatide 33 mcg / 1 ml; insulin glargine 100 units / 1 ml - insulin glargine - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sodium-glucose co-transporter-2 (sglt-2) inhibitors

Israel - English - Ministry of Health

sanofi israel ltd - insulin glargine; lixisenatide - solution for injection - lixisenatide 50 mcg / 1 ml; insulin glargine 100 units / 1 ml - insulin glargine - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sodium-glucose co-transporter-2 (sglt-2) inhibitors.

Israel - English - Ministry of Health

sanofi - aventis israel ltd - aluminium oxide hydrated 200 mg; dimethicone 25 mg - chewable tablets - combinations - antacid, antiflatulent, relief of sensation of heartburn.

Israel - English - Ministry of Health

sanofi - aventis israel ltd - aluminium oxide hydrated 460 mg; magnesium hydroxide 400 mg - suspension - combinations - for heartburn and gastroesophageal reflux.